- Home
- ARMK vs PCVX Comparison
ARMK vs PCVX Comparison
Compare ARMK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | PCVX |
|---|---|---|
| Founded | 1959 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 7.0B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARMK | PCVX |
|---|---|---|
| Price | $54.94 | $56.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $47.88 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 23.23 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $18,506,299,000.00 | N/A |
| Revenue This Year | $8.71 | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $48.94 | ★ N/A |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $35.07 | $33.62 |
| 52 Week High | $62.65 | $65.00 |
Technical Indicators
Market Signals| Indicator | ARMK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 40.28 |
| Support Level | $52.88 | $52.18 |
| Resistance Level | $58.58 | $58.77 |
| Average True Range (ATR) | 1.32 | 2.10 |
| MACD | -0.30 | -0.48 |
| Stochastic Oscillator | 16.29 | 21.28 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, is a foodservice company that provides facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving clients such as schools, healthcare facilities, and entertainment venues.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.